Evaxion Biotech announced that it has appointed Kim Bjoernstrup as Chairman of its Board of Directors. Evaxion also appointed Helen M. Boudreau to its Board of Directors and as Chair of the Audit Committee. Mr. Bjoernstrup has more than 25 years of leadership and management experience in the biotech and pharmaceutical industry, with Board positions at several companies, including as Chairman. Having worked at Danish healthcare companies Lundbeck and Coloplast, Kim was instrumental in the rapid growth of Swiss pharmaceutical company Octapharma and served as its Senior Vice President and Vice Chairman for 10 years. Subsequently, Kim co-founded the medical device company Xeltis; led a turnaround in sales and profitability as CEO of plasma company BPL Holdings and served as Chairman of Veloxis, a listed Denmark-based specialty pharmaceutical company. Kim holds a Master of Law from Copenhagen University. Ms. Boudreau has 30 years’ experience across biotech, pharmaceuticals, consulting and banking industries. Most recently, she was Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech. Previously, she served as CFO for NASDAQ-listed Proteostasis Therapeutics and privately held FORMA Therapeutics, after spending 16 years in senior finance and strategy roles at Novartis and Pfizer. She currently serves on the Board of Premier Inc., a NASDAQ-listed healthcare improvement company, as well as a private startup focused on mental health. She holds a BA in Economics from the University of Maryland and an MBA from the Darden School at the University of Virginia.